ORIGINAL ARTICLE
Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers
1
Department of Tumor Pathology, Greater Poland Cancer Centre, Poznań, Poland
2
Department of Oncologic Pathology and Prophylaxis, University of Medical Sciences, Poznań, Poland
3
Department of Pathology, Pomeranian Medical University, Szczecin, Poland
4
Laboratory of Cancer Genetics, Greater Poland Cancer Centre, Poznań, Poland
5
Research and Implementation Unit, Greater Poland Cancer Centre, Poznań, Poland
Submission date: 2024-01-16
Acceptance date: 2024-01-31
Publication date: 2024-05-27
Pol J Pathol 2024;75(2):105-114
KEYWORDS
TOPICS
ABSTRACT
Colorectal cancer is the third most common cancer worldwide and the second cause of death from malignant tumors. Colorectal cancers are treated with surgery, chemotherapy, gene therapy and immunotherapy. PD-1 and PD-L1 proteins have recently been considered as potential targets of anticancer therapy in colorectal cancer. The aim of this study was to evaluate the association of immunohistochemical expression of PD-1 and PD-L1 proteins in colorectal cancer patients with selected clinical and morphological parameters and their survival. Ninety-eight cases of colorectal cancer were studied.
Immunohistochemistry was used to evaluate the expression of PD-1 and PD-L1 proteins.
Correlations were found between the expression of PD-L1 protein in lymphocytes and lack of lymph node metastases and a lower clinical stage.
There was also a correlation between PD-L1 protein expression in cancer cells and a higher grade of histological malignancy.
Immunohistochemistry was used to evaluate the expression of PD-1 and PD-L1 proteins.
Correlations were found between the expression of PD-L1 protein in lymphocytes and lack of lymph node metastases and a lower clinical stage.
There was also a correlation between PD-L1 protein expression in cancer cells and a higher grade of histological malignancy.
REFERENCES (65)
1.
Phipps O, Brookes MJ, Al-Hassi HO. Iron deficiency, immunology, and colorectal cancer. Nutr Rev 2021; 79: 88-97.
2.
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet 2019; 394: 1467-1480.
3.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019; 16: 713-732.
4.
Bosman FT, Bujko K, Chmielik E, et al. Wybrane zagadnienia z patomorfologii i patokliniki jelita grubego i odbytu. Pol J Pathol 2014; 65: 32-36.
5.
Li J, Zhen L, Zhang Y, et al. Circ-104916 is downregulated in gas tric cancer and suppresses migration and invasion of gastric cancer cells. Onco Targets Ther 2017; 10: 3521-3529.
6.
Gao Y, Li SU, Xu D, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death- ligand 2 expression, and CD8 (+) T cell density in primary tumors and met astatic lymph nodes from patients with stage T1-4N+ M0 gastric adenocarcinoma. Chin J Cancer 2017; 36: 61-74.
8.
Markowska A, Sajdak S, Lubin J, et. al. Znaczenie PD-1 – receptora programowanej śmierci-1 – i jego ligandów w immunoterapii raka jajnika. Curr Gynecol Oncol 2016; 14: 117-120.
9.
Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982.
10.
Welz JA. The promise of PD-1 pathway blockade in the treatment of metastatic cancer. MOP Magnifier 2014; 1: 1-7.
11.
Lai CY, Tseng PC, Chen CL, et al. Different induction of PD-L1 (CD274) and PD-1 (CD279) expression in THP-1-differentiated types 1 and 2 macrophages. J Inflamm Res 2021; 14: 5241-5249.
12.
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
13.
Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
14.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
15.
Kalim M, Iqbal Khan MS, Zhan J. Programmed cell death ligand-1: a dynamic immune checkpoint in cancer therapy. Chem Biol Drug Des 2020; 95: 552-566.
16.
Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 2015; 15: 385.
17.
Cai J, Qi Q, Qian X, et al. The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer. J Cancer Res Clin Oncol 2019; 145: 1377-1385.
18.
Ghosh C, Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway. J Cancer 2021; 12: 2735-2746.
19.
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018; 18: 153-167.
20.
Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 2017; 355: 1428-1433.
21.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477.
22.
Willis BC, Sloan EA, Atkins KA, et al. Mismatch repair status and PDL1 expression in clear cell carcinomas of the ovary and endometrium. Mod Pathol 2017; 114: 106-107.
23.
Gangling T, Boran C, Jingzhang L, et al. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Med 2019; 8: 7044-7054.
24.
Nardone V, Tini P, Pastina P, et al. Radiomics predicts survival of patients with advanced non small cell lung cancer undergoing PD 1 blockade using nivolumab. Oncol Lett 2020; 19: 1559-1566.
25.
Biunno I, Paiola E, De Blasio P. The application of the tissue microarray (TMA) technology to analyze cerebral organoids. J Histochem Cytochem 2021; 69: 451-460.
26.
Koo M, Squires JM, Ying D, et al. Making a tissue microarray. Methods Mol Biol 2019; 1897: 313-323.
27.
Glinsmann-Gibson B, Wisner L, Stanton M, et al. Recommendations for tissue microarray construction and quality assurance. Appl Immunohistochem Mol Morphol 2020; 28: 325-330.
28.
Li Y, Liang L, Dai W, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 2016; 15: 55.
29.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer – ready for diagnostic practice? Human Pathology 2016; 47: 4-19.
30.
Lewandowska M. Ekspresja epireguliny i amfireguliny w komórkach nowotworowych i w komórkach mikrośrodowiska raków jelita grubego uzyskanych za pomocą laserowej mikrodyssekcji. Pomorski Uniwersytet Medyczny, Szczecin 2016.
31.
Hu WH, Chen HH, Yen SL, et al. Increased expression of interleukin-23 associated with progression of colorectal cancer. J Surg Oncol 2017; 115: 208-212.
32.
Lei Q, Wang D, Sun K, et al. Resistance mechanisms of anti- PD1/PDL1 therapy in solid tumors. Front Cell Dev Biol 2020; 8: 672.
33.
Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol 2019; 9: 396.
34.
Krawczyk P, Wojas-Krawczyk K. Przeciwciała monoklonalne przeciw immunologicznym punktom kontroli w leczeniu chorych na nowotwory. Onkol Prakty Klin 2015; 11: 76-86.
35.
Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15 -25.
36.
Geng Y, Zhang Q, Feng S, et al. Safety and efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Med 2021; 10: 1222-1239.
37.
Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017; 8: 1751.
38.
Choe EA, Cha YJ, Kim JH, et al. Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. Lung Cancer 2019; 136: 30-36.
39.
Chen S, Crabill GA, Pritchard TS, et al. Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 2019; 7: 305.
40.
Shan T, Chen S, Wu T, et al. PD-L1 expression in colon cancer and its relationship with clinical prognosis. Int J Clin Exp Pathol 2019; 12: 1764-1769.
41.
Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017; 66: 1463-1473.
42.
Zhao LW, Li C, Zhang RL, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 2014; 116: 1163-1168.
43.
Jeschke J, Bizet M, Desmedt C, et al. Dna methylation – based immune response signature improves patient diagnosis in multiple cancers. J Clin Invest 2017; 127: 3090-3102.
44.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.
45.
Hua D, Sun J, Mao Y, et al. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol 2012; 18: 971-978.
46.
Liang M, Li J, Wang D, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7- H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang province. Tumour Biol 2014; 35: 55-60.
47.
Song M, Chen D, Lu B, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821.
48.
Mansour MSI, Malmros K, Mager U, et al. PD-L1 expression in non-small cell lung cancer specimens: association with clinicopathological factors and molecular alterations. Int J Mol Sci 2022; 23: 4517.
49.
Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
50.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643-2648.
51.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
52.
Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
53.
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
54.
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
55.
Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
56.
Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016; 100: 88-98.
57.
Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in colorectal cancer: current and future strategies. J Anus Rectum Colon 2021; 5: 11-24.
58.
Lee LH, Cavalcanti MS, Segal NH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 2016; 29: 1433-1442.
59.
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, et al. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 2016; 29: 1104-1112.
60.
Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242.
61.
Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014; 25: 2178-2184.
62.
Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol 2014; 32: 1020-1030.
63.
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
64.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
65.
Grzywnowicz M, Giannopoulos K. Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. Acta Haematol Pol 2012; 43: 132-145.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
